MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fneur.2018.00302

Медицинская библиотека · Frontiers in neurology · 2018

STROKE34 Study Protocol: A Randomized Controlled Phase IIa Trial of Intra-Arterial CD34+ Cells in Acute Ischemic Stroke.

Sargento-Freitas João, Pereira Anabela, Gomes André, Amorim Paula, Matos Teresa, Cardoso Carla M P, Silva Fernando, Santo Gustavo Cordeiro, Nunes César, Galego Orlando, Carda José, Branco João, Lourenço Víctor, Cunha Luís, Ferreira Lino

СтатьяПеревод пока не подготовлен

Аннотация

RATIONALE/AIM: Despite the increasing efficacy of recanalization therapies for acute ischemic stroke, a large number of patients are left with long-term functional impairment, devoid of efficacious treatments. CD34+ cells comprise a subset of bone marrow-derived mononuclear cells with the capacity to promote angiogenesis in ischemic lesions and have shown promising results in observational and in vitro studies. In this study, we aim to assess the efficacy of an autotransplant of CD34+ cells in acute ischemic stroke.

SAMPLE SIZE ESTIMATES: 30 patients will be randomized for a power of 90% and alpha of 0.05 to detect a difference in 3 months infarct volume.

METHODS AND

DESIGN

We will screen 18-80 years old patients with acute ischemic stroke due to occlusion of a middle cerebral artery (MCA) for randomization. Persistent arterial occlusions, contra-indications to magnetic resonance imaging (MRI), premorbid dependency, or other severe diseases will be excluded. Treatment will involve bone marrow aspiration, selection of CD34+ cells, and their administration intra-arterially in the symptomatic MCA by angiography. Patients will be randomized for treatment at 7 (±2) days, 20 (±5 days) or sham procedure, 10 in each group.

STUDY OUTCOMES: The primary outcome will be infarct volume in MRI performed at 3 months. Secondary outcomes will include adverse events and multidimensional functional and neurological measures.

DISCUSSION/

CONCLUSION

STROKE34 is a PROBE design phase IIa clinical trial to assess the efficacy of intra-arterial administration of CD34+ cells 7 and 20 days after acute ischemic stroke.

TRIAL REGISTRATION EU CLINICAL TRIALS REGISTER: 2017-002456-88.

Для цитирования: Sargento-Freitas João, Pereira Anabela, Gomes André, Amorim Paula, Matos Teresa, Cardoso Carla M P, Silva Fernando, Santo Gustavo Cordeiro, Nunes César, Galego Orlando, Carda José, Branco João, Lourenço Víctor, Cunha Luís, Ferreira Lino. STROKE34 Study Protocol: A Randomized Controlled Phase IIa Trial of Intra-Arterial CD34+ Cells in Acute Ischemic Stroke.. Frontiers in neurology. 2018. DOI: 10.3389/fneur.2018.00302.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.